Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$68.70 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.15M
Market Cap
$14.76B
Enterprise Value$15.82B
Total Cash (Recent Filing)$1.24B
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 07, 2025EPS Estimate
1.01Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding158,300,000
10 Day Avg. Volume2,238,718
30 Day Avg. Volume2,148,702
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)6.08
Price to Sales (P/S)0.00
P/FCF Ratio16.48
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$105.67Price Target Upside12.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Illumina News
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of SomaLogic is seen as a solid strategic fit for Illumina, particularly given their prior relationship and the potential synergies over time.
Product And Market ExpansionSomaLogic bridges proteomics and genomics, enabling the detection of protein biomarkers for diseases, which enhances Illumina's offerings.
Revenue GrowthClinical penetration should support solid revenue growth as strong volumes from clinical customers are expected to lead to increased revenue growth.
Bears Say
Financial PerformanceMacroeconomic challenges and potential competitive threats have negatively impacted the company's financial performance and investor sentiment.
Market UncertaintyThe proteomics market is relatively nascent, and there is substantial uncertainty due to market conditions and potential margin dilution from SomaLogic.
Regulatory And Trade ChallengesIllumina faces significant headwinds from a recent import ban of its sequencers into China and continued uncertainty with respect to U.S. academic research funding.
Ownership Overview
2.71% Insiders
31.21% Mutual Funds
41.91% Other Institutional Investors
0.55% Public Companies and Individual Investors
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $14.76B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Aug 07, 2025 which is in 40 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on May 08, 2025. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of $3.104 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.01.
How many shares outstanding does Illumina have?
Illumina has 158,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $0.97 in its last earnings report, beating expectations of $0.94. Following the earnings report the stock price went down -4.8%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.67 (12.22% Upside)
$105.67 (12.22% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.12%
12-Months-Change
Fundamentals
Return on Equity
-23.82%
Trailing 12-Months
Asset Growth
-38.43%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong performance in certain areas like NovaSeq X placements and innovation pipeline advancements, but significant challenges in the Greater China region, research funding uncertainty, and tariff impacts. While growth areas show promise, the lowlights pose substantial risks.Read More>ILMN Revenue Breakdown
91.33% Sequencing
8.67% Microarray
ILMN Stock 12 Month Forecast
Average Price Target
$105.67
▲(12.22%Upside)